Zivo Bioscience to Deregister Securities, Cease Public Reporting; CFO and Director Resign

summarizeSummary

Zivo Bioscience announced its intention to deregister its securities and cease public reporting, citing cost-cutting measures, leading to the resignations of its Interim CFO and a Board Director.

check_boxKey Events

• Deregistration and Reporting Suspension

  Zivo Bioscience intends to file a Form 15 to voluntarily deregister its securities and suspend all SEC reporting obligations, including Forms 10-K, 10-Q, and 8-K, effective March 30, 2026.

• Executive and Board Resignations

  William A. Sullivan resigned as Interim Chief Financial Officer, effective March 30, 2026, and Alison A. Cornell resigned from the Board of Directors and all committees, effective March 26, 2026. These resignations are linked to the company's cost-cutting and deregistration strategy.

• Rationale for Going Private

  The company states that the significant financial burdens and administrative costs of public reporting are no longer in the best interests of the company and its stockholders, aiming to redirect resources to core business operations and achieve positive cash flow.

• Business Update Provided

  The CEO's letter to shareholders provided updates on anticipated meaningful revenue from the AgTech product line, progress in the Animal Health division (due diligence, Avian Influenza studies), and commercial interest in the Human Nutrition segment, aiming to reassure shareholders about underlying business strength.

auto_awesomeAnalysis

This filing signals a fundamental shift for Zivo Bioscience, as the company plans to exit the public market by voluntarily deregistering its securities and suspending all SEC reporting obligations. While the company frames this as a necessary cost-cutting measure to redirect resources towards core business operations and achieve positive cash flow, it represents a significant negative development for public shareholders. The cessation of public reporting will eliminate transparency and liquidity for investors, effectively ending the public investment thesis. The resignations of the Interim CFO and a Board Director are direct consequences of this strategic decision, further highlighting the company's pivot away from its public status. Investors should be aware of the severe implications for their ability to trade and obtain information about their holdings.